Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MARIA DIAB

Allopathic & Osteopathic Physicians Internal Medicine Hematology

NPI
1003259045
CMS profile
2781522
Location
DETROIT, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$126.31

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $126.31 1

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
Advanced Accelerator Applications $126.31 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MARIA DIAB

NPI 1003259045 · CMS profile ID 2781522

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology

DETROIT, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1003259045?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MARIA DIAB, NPI 1003259045, CMS profile ID 2781522. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1003259045?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). MARIA DIAB, NPI 1003259045, CMS profile ID 2781522. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1003259045?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
MARIA DIAB, NPI 1003259045, CMS profile ID 2781522, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1003259045?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $126.31 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Advanced Accelerator Applications $126.3103/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727218419 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $660.78 7
PY2020 $126.31 1
PY2022 $725.89 2
PY2024 $1,640.00 1
PY2025 $481.87 5

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2022, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2022 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $278,038.14 14
PY2024 Principal investigator $41,330.00 11
PY2023 Principal investigator $187,105.60 14
PY2022 Principal investigator $315,471.91 9
PY2021 Principal investigator $5,033.00 4

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

14 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 2 AstraZeneca Pharmaceuticals LP $185.02 12/31/2023 Covered Recipient Teaching Hospital
Emory University Hospital
A Phase 1b/2, Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of Oleclumab (MEDI9447) with or without Durvalumab in combination with Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma No dispute reported 06/30/2026 991129235
Principal investigator 1 Merck Sharp & Dohme LLC $371.38 12/31/2023 Covered Recipient Teaching Hospital
Emory University Hospital
A Phase I,II Open-Label, Safety And Preliminary Efficacy Study Of MRx0518 In Combination With Pembrolizumab In Patients With Advanced Malignancies Who Have Progressed On PD-1 Inhibitors No dispute reported 06/30/2026 1042488209
Principal investigator 1 Merck Sharp & Dohme LLC $7,287.65 12/31/2023 Covered Recipient Teaching Hospital
Emory University Hospital
A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine,Cisplatin versus Placebo Plus Gemcitabine,Cisplatin as First-Line Therapy in Participants with Advanced and,or Unresectable Biliary Tract Carcinoma No dispute reported 06/30/2026 1042513295
Principal investigator 1 Merck Sharp & Dohme LLC $1,560.00 11/08/2023 Covered Recipient Teaching Hospital
Emory University Hospital
A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine,Cisplatin versus Placebo Plus Gemcitabine,Cisplatin as First-Line Therapy in Participants with Advanced and,or Unresectable Biliary Tract Carcinoma No dispute reported 06/30/2026 1042513283
Principal investigator 1 Mirati Therapeutics, Inc. $3,696.00 07/07/2023 Covered Recipient Teaching Hospital
EMORY UNIVERSITY HOSPITAL
A Randomized Phase 3 Study of MRTX849 in Combination With Cetuximab Versus Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation With Disease Progression On or After Standard First-Line Therapy No dispute reported 06/30/2026 1057984987
Principal investigator 1 Novartis Pharmaceuticals Corporation $4,573.50 06/29/2023 Non-covered Recipient Entity
EMORY UNIVERSITY OFFICE OF GRANTS AND CONTRACTS
Phase Ib Study of Gevokizumab in Combination With Standard of Care Anti-cancer Therapies in Patients With Metastatic Colorectal Cancer, Gastroesophageal Cancer and Renal Cell Carcinoma No dispute reported 06/30/2026 1017237079
Principal investigator 1 GlaxoSmithKline, LLC. $3,335.00 06/15/2023 Non-covered Recipient Entity
EMORY UNIVERSITY
A FIRST-TIME-IN-HUMAN OPEN-LABEL STUDY TO ASSESS SAFETY AND TOLERABILI No dispute reported 06/30/2026 1006248219
Principal investigator 1 GlaxoSmithKline, LLC. $660.00 06/15/2023 Non-covered Recipient Entity
EMORY UNIVERSITY
A FIRST-TIME-IN-HUMAN OPEN-LABEL STUDY TO ASSESS SAFETY AND TOLERABILI No dispute reported 06/30/2026 1006248225
Principal investigator 1 GlaxoSmithKline, LLC. $4,950.00 06/15/2023 Non-covered Recipient Entity
EMORY UNIVERSITY
A FIRST-TIME-IN-HUMAN OPEN-LABEL STUDY TO ASSESS SAFETY AND TOLERABILI No dispute reported 06/30/2026 1006248231
Principal investigator 1 Mirati Therapeutics, Inc. $26,617.80 05/31/2023 Covered Recipient Teaching Hospital
EMORY UNIVERSITY HOSPITAL
A Randomized Phase 3 Study of MRTX849 in Combination With Cetuximab Versus Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation With Disease Progression On or After Standard First-Line Therapy No dispute reported 06/30/2026 1057984981
Principal investigator 1 Mirati Therapeutics, Inc. $22,342.00 04/19/2023 Covered Recipient Teaching Hospital
EMORY UNIVERSITY HOSPITAL
A Randomized Phase 3 Study of MRTX849 in Combination With Cetuximab Versus Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation With Disease Progression On or After Standard First-Line Therapy No dispute reported 06/30/2026 1057984975
Principal investigator 3 AstraZeneca Pharmaceuticals LP $7,756.73 03/15/2023 Covered Recipient Teaching Hospital
Emory University Hospital
A Phase 1b/2, Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of Oleclumab (MEDI9447) with or without Durvalumab in combination with Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma No dispute reported 06/30/2026 991138181
Principal investigator 2 AstraZeneca UK Limited $95,507.32 02/20/2023 Covered Recipient Teaching Hospital
Emory University Hospital
A Phase I/IIa First-in-human Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD8853 in Participants with Selected Advanced/Metastatic Solid Tumours No dispute reported 06/30/2026 991128019
Principal investigator 1 Mirati Therapeutics, Inc. $8,263.20 01/26/2023 Covered Recipient Teaching Hospital
EMORY UNIVERSITY HOSPITAL
A Randomized Phase 3 Study of MRTX849 in Combination With Cetuximab Versus Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation With Disease Progression On or After Standard First-Line Therapy No dispute reported 06/30/2026 1057984969